SYK and B-cell non-Hodgkin lymphoma: Indeed, increased activity or overexpression of SYK is associated with worse prognosis of patients with acute myeloid leukemia, chronic lymphocytic leukemia, or T- or B-cell lymphoma [11–15], while SYK knockdown or inhibition induces apoptosis both in vitro and in vivo [15, 16].